Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: Efficacy, security and cost analysis

Journal of Nephrology

Volumn 19, Issue 5, 2006, Pages 648-655

  Gainza, Francisco J ^a   Quintanilla, Nuria ^a   Pijoan, Jose I ^a   Delgado, Sonia ^a   Urbizu, Jose M ^a   Lampreabe, Ildefonso ^a,b  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Anticoagulation; Continuous renal replacement therapies; Epoprostenol; Filter duration; Hemodiafiltration; Hemofiltration; Heparin; Platelets; Prostacyclin; Prostaglandins

Indexed keywords

HEPARIN; PROSTACYCLIN; VASOACTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRACORPOREAL CIRCULATION; FEMALE; HEMODIAFILTRATION; HUMAN; HYPERCOAGULABILITY; HYPOTENSION; LOW DRUG DOSE; MALE; MUCOSAL BLEEDING; RENAL REPLACEMENT THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

ANTICOAGULANTS; BLOOD PRESSURE; COSTS AND COST ANALYSIS; DRUG TOXICITY; EPOPROSTENOL; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA; THROMBOPHILIA; TIME FACTORS; VASODILATOR AGENTS;

EID: 33947202575     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schetz M. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol 2001; 132: 283-303.
2. Gainza FJ, Minguela JI, Urbizu JM, Lampreabe I. Anticoagulation with low-dose un-fractionated heparin in continuous renal replacement therapies: coagulation parameters and filter life span [abstracts]. Kidney Int 1999; 55: 363-4.
3. Scheel P, Eustace J, Rabb H. Continuous dialysis as systemic therapy in the critically ill patient? Crit Care Med 2003; 31: 988-9.
4. O'Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003; 16: 61-7.
5. Smyth EM, FitzGerald GA. Human prostacyclin receptor. Viram Horm 2002; 65: 149-65.
6. O'Grady J, Warrington S, Moti M, Bunting S, Flower R, Fowle AS, Higgs EA, Moncada S. Effects of intravenous infusion of prosmcyclin (PGI2) in man. Prostaglandins 1980; 19: 319-32.
7. Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, Felfenig M, Zimpfer M. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Crit Care Med 2003; 31: 864-8.
8. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneons and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 06: 431-7.
9. Journois D, Chanu D, Pouard P, Mauriat P, Safran D. Assessment of standardized ultrafiltrate production rate using prostacyclin in continuous venovenous hemofiltration. Contrib Nephrol 1991; 93: 202-4.
10. Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med 1993; 19: 329-32.
11. Meyer MM. Renal replacement therapies. Crit Care Clin 2000; 16: 29-58.
12. Nielsen CB, Bech JB, Pedersen EB. Effects of prostacyclin on renal hemodinamycs, renal tubular function and vasoactive hormones in healthy humans: a placebo-controlled dose-response study. Br J Clin Pharmacol 1997; 44: 471-6.
13. Skrinska VA, Lucas FV, Chisolm GM, Hesse BL. Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. J Lab Clin Med 1986; 107: 187-93.
14. Ponikvar R, Kandus A, Buturovic J, Kyeder R. Use of prostacyclin as the only anticoagulant during continuous venovenous hemofiltration. Contrib Nephrol 1991; 93: 218-20.
15. Lagenecker SA, Felferning M, Werba A, Mueller CM, Chiari A, Zimpfer M. Anticoagulation with prostacyclin and heparin during continuous venovenons hemofiltration. Crit Care Med 1994; 22: 1774-81.
16. Zobel G, Trop M, Muntean W, Ring E, Gleispach H. Anticoagulation for continuous arteriovenous hemofiltration in children. Blood Purif 1988, 6: 90-5.
17. Klotz KF, Gellersen H, Brzelinski T. Use of prostacyclin with continuous hemofiltration after open-heart surgery. Contrib Nephrol 1995; 116: 136-9.
18. Kozek-Langenecker SA, Kettner SC, Oismueller C, Gonano C, Speiser W, Zimfer M. Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration. Crit Care Med 1998; 26: 1208-12.
19. Kozek-Langenecker SA, Spiss Cg, Gamsjager T, Domenig C, Zimpfer M. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wien Klin Wochenschr 2002; 114: 96-101.
20. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006; 32: 188-202.
21. Mehta RL, McDonald BR, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis: an update after 12 months. Contrib Nephrol 1991; 93: 210-4.
22. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55: 1991-7.
23. Cointault O, Kamar N, Bories P, Lavayssiere L, Angles O, Rostaing L, Genestal M, Durand D. Regional citrate anticoagulation in continuous venovenous haemodiafiltrafion using commercial solutions. Nephrol Dial Transplant 2004; 19: 171-8.
24. Fischer KG, van de Lee A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int 1999; 56 (Suppl 72): S46-50.
25. Frank RD, Farber H, Stefanidis I, Lanzmich R, Kierdof HP. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. Kidney Int 1999; 50 (Suppl 72): S41-5.
26. Fiaccadori E, Maggiore U, Rotelli C, Minari M, Melfa L, Cappe G, Cabassi A. Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med 2002; 28: 586-93.